Healthcare Industry News: TAVO
News Release - May 30, 2019
Dr. Gustavo Mahler Joins Dynamk Capital as Venture PartnerNEW YORK, May 30, 2019 -- (Healthcare Sales & Marketing Network) -- Dr. GusTAVO Mahler joins Dynamk Capital as a Venture Partner after leaving his 10 year tenure with AGC Biologics (formerly CMC Biologics). Under his leadership as CEO of AGC Biologics, the company grew to become a leader in biologics contract development and manufacturing with operations in the United States, Europe, and Asia. GusTAVO comes to Dynamk Capital with a wealth of industry knowledge specifically related to the development and commercialization of biologics. While at AGC Biologics, he successfully supported clients from pre-clinical through commercial production for over 150 biologics programs, while successfully guiding customers through the regulatory approval processes. GusTAVO was a key player in the sale of CMC Biologics to the Asahi Glass Corporation for EUR 520 million in 2017.
"I am thrilled about joining Dynamk Capital at this point in my career," GusTAVO commented, "my background and business experience are a perfect fit to support Dynamk's model and investment targets."
Throughout his career, which also included a role as VP Technical Operations at Bayer Healthcare, GusTAVO has been involved in all aspects of biomanufacturing including large scale cell culture and protein manufacturing, purification, solid and liquid formulation including aseptic filling, and facility operation under cGMP guidelines. He has a real-life understanding of the challenges facing biomanufacturers and the implementation of tools, technologies, and services to address them. His insights will be invaluable as part of the team at Dynamk Capital evaluating new technologies and guiding companies in Dynamk's growing portfolio.
Daniella Kranjac, Co-Founder and Managing Director of Dynamk Capital explains the significance of this addition to the team:
"I have had the great pleasure of working with GusTAVO over the years on several projects related to the rapid manufacturing expansion of CMC Biologics and more recently as an Advisor to Dynamk Capital. I know first-hand how he can bring value to the fund and our portfolio companies. Over the past year we have been building our team of top performers and industry leaders, and I am excited to be working with GusTAVO in an expanded capacity."
About Dynamk Capital
Dynamk Capital LLC is a venture capital firm investing in early stage life sciences companies. Dynamk's investment strategy is centered on identifying companies developing disruptive technologies, tools, and services that enable the full biopharma continuum across discovery, development, and manufacturing of therapeutics. The Dynamk team includes experienced life science entrepreneurs, investors, advisors, and subject matter experts. Please visit www.dynamk.vc for more information.
Source: Dynamk Capital
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.